Aquestive Therapeutics, Inc. AQST Capitalized Contract Costs, Net
Capitalized Contract Costs, Net at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CapitalizedContractCostNet.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s capitalized contract costs, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s capitalized contract costs, net?
- Aquestive Therapeutics, Inc. (AQST) reported capitalized contract costs, net of $442K in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s capitalized contract costs, net changed year-over-year?
- Aquestive Therapeutics, Inc.'s capitalized contract costs, net decreased by 6.4% year-over-year, from $472K to $442K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s capitalized contract costs, net?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s capitalized contract costs, net has grown at a -20.8% compound annual growth rate (CAGR), from $715K to $449K.
- What does capitalized contract costs, net mean?
- This represents the unamortized balance of costs incurred to obtain or fulfill customer contracts that are recognized as assets rather than immediate expenses. These costs are systematically amortized over the expected duration of the contract benefit. Investors use this to evaluate the efficiency of sales and marketing efforts and the timing of expense recognition relative to revenue generation.